Literature DB >> 24420080

A CD40/CD40L feedback loop drives the breakdown of CD8(+) T-cell tolerance following depletion of suppressive CD4(+) T cells.

Sabine Muth1, Kristian Schütze, Tobias Hain, Hideo Yagita, Hansjörg Schild, Hans Christian Probst.   

Abstract

Dendritic cells (DCs) are the key APCs not only for the priming of naïve T cells, but also for the induction and maintenance of peripheral T-cell tolerance. We have recently shown that cognate interactions between Foxp3(+) Tregs and steady-state DCs are crucial to maintain the tolerogenic potential of DCs. Using DIETER mice, which allow the induction of antigen presentation selectively on DCs without altering their maturation status, we show here that breakdown of CD8(+) T-cell tolerance, which ensues after depletion of suppressive CD4(+) T cells, is driven by a positive feedback loop in which autoreactive CD8(+) T cells activate DCs via CD40. These data identify ligation of CD40 on DCs as a stimulus that promotes autoreactive T-cell priming when regulatory T-cell suppression fails and suggest that feedback from autoreactive T cells to DCs may contribute to the well-documented involvement of CD40 in many autoimmune diseases.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CD40 ligation; CD8+ T cells; Dendritic cells; Peripheral tolerance

Mesh:

Substances:

Year:  2014        PMID: 24420080     DOI: 10.1002/eji.201343738

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  2 in total

1.  Neoantigen Expression in Steady-State Langerhans Cells Induces CTL Tolerance.

Authors:  Helen Strandt; Douglas Florindo Pinheiro; Daniel H Kaplan; Dagmar Wirth; Iris Karina Gratz; Peter Hammerl; Josef Thalhamer; Angelika Stoecklinger
Journal:  J Immunol       Date:  2017-07-24       Impact factor: 5.422

2.  CD27 expression on Treg cells limits immune responses against tumors.

Authors:  Sabine Muth; Annekatrin Klaric; Markus Radsak; Hansjörg Schild; Hans Christian Probst
Journal:  J Mol Med (Berl)       Date:  2021-08-23       Impact factor: 4.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.